HRP20201902T1 - Pripravci protiv raka - Google Patents

Pripravci protiv raka Download PDF

Info

Publication number
HRP20201902T1
HRP20201902T1 HRP20201902TT HRP20201902T HRP20201902T1 HR P20201902 T1 HRP20201902 T1 HR P20201902T1 HR P20201902T T HRP20201902T T HR P20201902TT HR P20201902 T HRP20201902 T HR P20201902T HR P20201902 T1 HRP20201902 T1 HR P20201902T1
Authority
HR
Croatia
Prior art keywords
solid dispersion
formulation
arn
poly
meth
Prior art date
Application number
HRP20201902TT
Other languages
English (en)
Croatian (hr)
Inventor
Geert Verreck
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20201902(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Publication of HRP20201902T1 publication Critical patent/HRP20201902T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20201902TT 2014-12-05 2015-12-03 Pripravci protiv raka HRP20201902T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196591 2014-12-05
EP15817642.0A EP3226842B1 (en) 2014-12-05 2015-12-03 Anticancer compositions
PCT/US2015/063667 WO2016090101A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (1)

Publication Number Publication Date
HRP20201902T1 true HRP20201902T1 (hr) 2021-07-23

Family

ID=52006905

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201902TT HRP20201902T1 (hr) 2014-12-05 2015-12-03 Pripravci protiv raka

Country Status (31)

Country Link
US (3) US20170360707A1 (enExample)
EP (2) EP3842034B1 (enExample)
JP (1) JP6767368B2 (enExample)
KR (1) KR102348325B1 (enExample)
CN (2) CN115837010B (enExample)
AR (1) AR102924A1 (enExample)
AU (1) AU2015358493B2 (enExample)
CA (1) CA2969661C (enExample)
CL (1) CL2017001372A1 (enExample)
CO (1) CO2017005573A2 (enExample)
CR (1) CR20170217A (enExample)
CY (1) CY1123856T1 (enExample)
DK (1) DK3226842T3 (enExample)
EA (1) EA035988B1 (enExample)
ES (2) ES3021508T3 (enExample)
HR (1) HRP20201902T1 (enExample)
HU (1) HUE051888T2 (enExample)
IL (1) IL252324B (enExample)
LT (1) LT3226842T (enExample)
MA (2) MA55404A (enExample)
MD (1) MD3226842T2 (enExample)
MX (1) MX384382B (enExample)
NI (1) NI201700069A (enExample)
PL (1) PL3226842T3 (enExample)
PT (1) PT3226842T (enExample)
RS (1) RS61466B1 (enExample)
SG (1) SG11201704264UA (enExample)
SI (1) SI3226842T1 (enExample)
TW (1) TWI683662B (enExample)
UA (1) UA121123C2 (enExample)
WO (1) WO2016090101A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
SG11201704267VA (en) 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
KR102387089B1 (ko) 2014-12-05 2022-04-14 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
BR112020007439A2 (pt) 2017-10-16 2020-10-27 Aragon Pharmaceuticals, Inc. antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastática
EP3773509B1 (en) * 2018-04-06 2023-11-01 Capsugel Belgium NV Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
WO2020144647A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising apalutamide dispersed in apple sauce
TWI840496B (zh) 2019-01-30 2024-05-01 美商艾瑞岡醫藥公司 用於治療轉移性去勢敏感性前列腺癌之抗雄性激素
AU2020215177A1 (en) 2019-01-30 2021-08-12 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CA3160121A1 (en) 2019-11-04 2021-05-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
KR20250157532A (ko) 2023-03-16 2025-11-04 바이엘 컨수머 케어 악티엔게젤샤프트 호르몬 감수성 전립선암의 생화학적 재발이 있는 환자의 치료를 위한 안드로겐 수용체 길항제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080902A1 (en) 2001-04-02 2002-10-17 Astrazeneca Ab Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
JPWO2003077827A1 (ja) * 2002-03-19 2005-07-14 日本新薬株式会社 医薬固体分散体の製造方法
AU2003292509B2 (en) * 2003-12-15 2007-08-02 Council Of Scientific And Industrial Research Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
DK2656842T3 (en) * 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
CA2787083C (en) * 2010-02-16 2018-05-22 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
AU2012271403C1 (en) * 2011-06-15 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
HUE038082T2 (hu) 2012-06-07 2018-09-28 Aragon Pharmaceuticals Inc Androgén receptor modulátor kristályformái
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
SI3725778T1 (sl) * 2012-09-11 2022-02-28 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
UA117663C2 (uk) * 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
PE20151335A1 (es) * 2013-01-22 2015-09-18 Hoffmann La Roche Composicion farmaceutica con biodisponibilidad mejorada
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
BR112016002970A2 (pt) * 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
WO2015118015A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists

Also Published As

Publication number Publication date
AU2015358493B2 (en) 2021-05-06
CY1123856T1 (el) 2022-05-27
MX2017007201A (es) 2018-01-30
UA121123C2 (uk) 2020-04-10
NI201700069A (es) 2017-10-31
TWI683662B (zh) 2020-02-01
LT3226842T (lt) 2021-03-25
JP6767368B2 (ja) 2020-10-14
US20240293321A1 (en) 2024-09-05
EA035988B1 (ru) 2020-09-09
CN115837010A (zh) 2023-03-24
CA2969661C (en) 2023-04-25
CL2017001372A1 (es) 2018-01-05
BR112017011787A2 (pt) 2017-12-26
MA55404A (fr) 2022-02-02
KR102348325B1 (ko) 2022-01-06
IL252324B (en) 2021-10-31
AU2015358493A1 (en) 2017-06-08
RS61466B1 (sr) 2021-03-31
EA201791252A1 (ru) 2017-10-31
CO2017005573A2 (es) 2017-09-29
CA2969661A1 (en) 2016-06-09
WO2016090101A1 (en) 2016-06-09
ES2839128T3 (es) 2021-07-05
MX384382B (es) 2025-03-14
MD3226842T2 (ro) 2021-03-31
CR20170217A (es) 2017-08-30
AR102924A1 (es) 2017-04-05
PT3226842T (pt) 2020-12-23
HUE051888T2 (hu) 2021-03-29
IL252324A0 (en) 2017-07-31
US20220151931A1 (en) 2022-05-19
JP2017536401A (ja) 2017-12-07
SI3226842T1 (sl) 2021-04-30
SG11201704264UA (en) 2017-06-29
CN115837010B (zh) 2025-03-14
ES3021508T3 (en) 2025-05-27
EP3842034A1 (en) 2021-06-30
PL3226842T3 (pl) 2021-07-12
KR20170086657A (ko) 2017-07-26
EP3226842B1 (en) 2020-11-25
EP3842034B1 (en) 2025-02-12
EP3226842A1 (en) 2017-10-11
MA41108B1 (fr) 2021-03-31
TW201632187A (zh) 2016-09-16
DK3226842T3 (da) 2021-01-25
CN106999430A (zh) 2017-08-01
US20170360707A1 (en) 2017-12-21
MA41108A (fr) 2016-06-09

Similar Documents

Publication Publication Date Title
HRP20201902T1 (hr) Pripravci protiv raka
HRP20211140T1 (hr) Pripravci protiv raka
HRP20241719T1 (hr) Antitumorske smjese
JP2017536401A5 (enExample)
JP2017536407A5 (enExample)
JP2017536398A5 (enExample)
Li et al. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets
JP2014516080A5 (enExample)
PE20181925A1 (es) Composiciones antineoplasicas
TN2014000441A1 (en) A delayed release drug formulation
MX352907B (es) Composiciones de un poliortoéster y un solvente aprótico.
ZA201802706B (en) Compositions and methods of manufacturing protein microparticles
RU2015128609A (ru) Перенасыщенные стабилизированные наночастицы для слаборастворимых лекарственных средств
JP2014528431A5 (enExample)
CN104224723A (zh) 一种泊马度胺纳米粒、制剂及其制备方法
HRP20161340T1 (hr) Formulacije darunavira
HRP20200780T1 (hr) Formulacija za kontrolirano otpuštanje hidrokortizona
RU2016102605A (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
Singh et al. Evaluation of enhancement of solubility of paracetamol by solid dispersion technique using different polymers concentration
Roy et al. Composite alginate hydrogel microparticulate delivery system of zidovudine hydrochloride based on counter ion induced aggregation
ES2951884T3 (es) Novedosa composición de recubrimiento de película
PH12018500304A1 (en) A delyade release drug formulation
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
HRP20161794T1 (hr) Novi terapijski pristupi za liječenje neuroinflamatornih stanja
PE20230830A1 (es) Formulaciones farmaceuticas de acetato de abiraterona y niraparib